Related Experiment Videos
Cisplatin-based neoadjuvant chemotherapy for invasive bladder cancer
1Department of Urology, Hiroshima University School of Medicine, Japan.
Hiroshima Journal of Medical Sciences
|December 1, 1995
Summary
Neoadjuvant M-VAC chemotherapy showed a 38% response rate in locally advanced bladder cancer patients. Pathological responders had significantly better survival, indicating potential prognostic improvement.
Area of Science:
- Oncology
- Urology
- Chemotherapy
Background:
- Locally advanced bladder cancer requires effective treatment strategies.
- Neoadjuvant chemotherapy aims to downstage tumors and improve surgical outcomes.
Purpose of the Study:
- To evaluate the efficacy of neoadjuvant methotrexate, vinblastine, epirubicin (doxorubicin), and cisplatin (M-VAC) chemotherapy.
- To assess the response rate and survival outcomes in patients with locally advanced bladder cancer.
Main Methods:
- 24 patients with locally advanced bladder cancer (stages T2-4N0-3M0) received neoadjuvant M-VAC chemotherapy.
- Surgical intervention (cystectomy) followed chemotherapy.
- Pathological response and survival rates were analyzed.
Main Results:
- Overall pathological response rate was 38% (complete response: 4%, partial response: 33%).
- Patients achieving a pathological response demonstrated significantly higher survival rates (p <0.01).
- Clinical T2 and T3a stages showed higher response rates (64%) compared to T3b and T4 stages (15%).
Conclusions:
- Neoadjuvant M-VAC chemotherapy is a viable option for locally advanced bladder cancer.
- Pathological response to neoadjuvant chemotherapy correlates with improved survival.
- Further follow-up is necessary to confirm long-term survival benefits.